Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ernexa Therapeutics Inc.NTN · Entity 8278 | Director | June 08, 2017 | June 09, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ernexa Therapeutics Inc.
Report date June 08, 2017 · Filed June 09, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.31 · Expires 2027-06-07 | Direct | 400 |
Reported balance
After 2017-06-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-06-08 · Grant · Acquired 400 · Balance 400 F1: Stock option granted under the NTN Buzztime, Inc. Amended 2010 Performance Incentive Plan. The options vest and become exercisable in 12 equal monthly installments from the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Stock option granted under the NTN Buzztime, Inc. Amended 2010 Performance Incentive Plan. The options vest and become exercisable in 12 equal monthly installments from the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 08, 2017 Filed Jun 9, 2017 20:34 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | GrantStock Options (Right to Buy) · Derivative | 400 | $0.00 Strike: $6.31 | $0.00 |
DisclosureSEC source: 0001493152-17-006432 · form4.xml · derivative · entry 1 Lewis Mary Beth · CIK 0001456637 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400 Underlying: Common Stock · 400 shares Expires 2027-06-07 F1 · derivative.exercise_date: Stock option granted under the NTN Buzztime, Inc. Amended 2010 Performance Incentive Plan. The options vest and become exercisable in 12 equal monthly installments from the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.